BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

  March 24, 2026

   · 

  1 min read
• Press Releases

  HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

  March 24, 2026

   · 

  3 min read
• Press Releases

  Fosun Pharma Announces 2025 Annual Results

  March 24, 2026

   · 

  10 min read
• Press Releases

  Pixee Medical Announces CE Mark for Knee+ NexSight and Performs Europe’s First Augmented Reality Knee Surgeries

  March 24, 2026

   · 

  3 min read
• Press Releases

  CVAUSA Offers Heartflow Technology to Elevate Cardiovascular Diagnostics Across Its Expansive Network

  March 24, 2026

   · 

  3 min read
• Press Releases

  TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box

  March 24, 2026

   · 

  1 min read
• Press Releases

  Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies

  March 24, 2026

   · 

  3 min read
• 

  FDA

  Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug

  While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.

  March 24, 2026

   · 

  3 min read

   · 

  Heather McKenzie